Abstracts tagged "patient-reported outcome measures"

Abstract Number: 1476 • 2017 ACR/ARHP Annual Meeting
Effect of Treat-to-Target Tocilizumab- and Methotrexate-Based Strategies on Health-Related Quality of Life in Newly Diagnosed Rheumatoid Arthritis Patients: Results of the U-Act-Early Trial
Xavier M Teitsma¹, Johannes WG Jacobs¹, Paco MJ Welsing², Attila Pethö-Schramm³, Michelle EA Borm⁴, Jacob M. van Laar⁵, Floris PJ Lafeber⁵ and Johannes W.J. Bijlsma², ¹Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ³F. Hoffmann-La Roche, Basel, Switzerland, ⁴Beneluxlaan 2a, Roche Nederland BV, Woerden, Netherlands, ⁵Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: Patient-reported outcomes are, in addition to other efficacy and safety related outcomes, important reflections of effectiveness and adverse effects of a therapy. The Outcomes…
Abstract Number: 1477 • 2017 ACR/ARHP Annual Meeting
Patient-Reported Outcomes As Independent Measures of Treatment Success with Sirukumab, an Anti-IL6 Cytokine Monoclonal Antibody, in Patients with Active Rheumatoid Arthritis: Post-Hoc Analysis of 2 Placebo-Controlled Phase 3 Trials
Vibeke Strand¹, Rita Ganguly², Nan Li³, Prasheen Agarwal³, Shihong Sheng³, Kaiyin Fei³, Kelly McQuarrie³ and Sharon Popik³, ¹Division of Immunology/Rheumatology, Stanford University, Stanford, CA, ²GlaxoSmithKline, Collegeville, PA, ³Janssen Research & Development, LLC, Spring House, PA
Background/Purpose: Sirukumab, a selective, high-affinity, human anti–IL-6 monoclonal antibody, is in development for rheumatoid arthritis (RA) and other diseases. Effects of sirukumab on RA symptoms…
Abstract Number: 2242 • 2017 ACR/ARHP Annual Meeting
Pattern and Influential Factors in Promoting Treat-to-Target (T2T) for Follow-up RA Patients with a Rheumatologist-Patient Interactive Smart System of Disease Management (SSDM): A Cohort Study from China
Rong Mu¹, Jing Yang², Hua Wei³, Wenqiang Fan⁴, Jianlin Huang⁵, Hongzhi Wang⁶, Jinli Ru⁷, Yongfu Wang⁸, Jinmei Zou², Jianling Dong², Xinwang Duan⁹, Fang He¹⁰, Xiaofei Shi¹¹, Xiafei Xin¹², Fei Xiao¹³, Hui Xiao¹³, Yuhua Jia¹³, Minjun Wang¹³, Lijun He¹³, Rui Bai¹³, Xiyao Huang¹³, Bing Wu¹³ and Zhanguo Li¹⁴, ¹Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China, ²Department of rheumatology, Central Hospital of MianYang, Sichuan, Mian Yang, China, ³No 98,Nantong West Rd,Yangzhou, Northern Jiangsu People's Hospital, Yangzhou, China, ⁴Department of rheumatology, Central Hospital of XinXiang, Henan, XinXiang, China, ⁵Department of rheumatology, The Sixth Hospital Affiliated to Sun yat-sen University, Guangzhou, China, ⁶The First Hospital of Jiaxing, Jiaxing, China, ⁷The 264th Hospital of the PLA, Taiyuan, China, ⁸The First Affiliated Hospital of BaoTou Medical College, Baotou, China, ⁹Department of rheumatology, The Second Affiliated Hospital of Nanchang University, Nanchang, China, ¹⁰Central Hospital of Sui Ning, Sichuan, Suining, China, ¹¹The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, China, ¹²Ningbo First Hospital, Zhejiang, Ningbo, China, ¹³Gothic Internet Technology Corporation, Shanghai, China, ¹⁴Rheum/Immunology, Peking University People's Hospital, Beijing, China
Background/Purpose: Treat-to-Target (T2T), achieving a DAS28 lower than 2.6 (remission) or below 3.2 (low disease activity), is the main management strategy. The Smart System of…
Abstract Number: 2884 • 2017 ACR/ARHP Annual Meeting
A Phase 2 Study of Safety and Efficacy of Anabasum (JBT-101), a Cannabinoid Receptor Type 2 Agonist, in Diffuse Cutaneous Systemic Sclerosis
Robert F. Spiera¹, Laura K. Hummers², Lorinda Chung³, Tracy M. Frech⁴, Robyn T. Domsic⁵, Vivien Hsu⁶, Daniel E. Furst⁷, Jessica K. Gordon¹, Maureen D. Mayes⁸, Robert W. Simms⁹, Scott Constantine¹⁰ and Barbara White¹⁰, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Medical and Rheumatology, Johns Hopkins University, Baltimore, MD, ³Rheumatology, Stanford University Medical Center, Palo Alto, CA, ⁴Division of Rheumatology, University of Utah, Salt Lake City, UT, ⁵Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁶Rheumatology, Robert Wood Johnson University Scleroderma Program, New Brunswick, NJ, ⁷David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁸University of Texas McGovern Medical School, Houston, TX, ⁹Rheumatology, Boston University School of Medicine, Boston, MA, ¹⁰Corbus Pharmaceuticals, Inc., Norwood, MA
Background/Purpose: Systemic sclerosis (SSc) is characterized in part by chronic activation of the innate immune system with fibrosis. Anabasum is a non-immunosuppressive, synthetic, orally administered…
Abstract Number: 2953 • 2017 ACR/ARHP Annual Meeting
Drivers of Satisfaction with Care in Lupus
Bhavika Sethi¹, Ailda Nika², Winston Sequeira³, Joel A. Block⁴, Sergio Toloza⁵, Ana Bertoli⁶, Ivana Blazevic⁷, Luis M. Vilá⁸, Ioana Moldovan⁹, Karina Torralba¹⁰, Davide Mazzoni¹¹, Elvira Cicognani¹¹, Sarfaraz Hasni¹², Berna Goker¹³, Seminur Haznedaroglu¹³, Josiane Bourré-Tessier¹⁴, Sandra V. Navarra¹⁵, Chi Chiu Mok¹⁶, Ann Clarke¹⁷, Michael Weisman¹⁸, Daniel J. Wallace¹⁹ and Meenakshi Jolly³, ¹University of Birmingham, Birmingham, United Kingdom, ²Rheumatology, Rush University Medical Center, Chicago, IL, ³Department of Medicine, Section of Rheumatology, Rush University Medical Center, Chicago, IL, ⁴Division of Rheumatology, Rush University Medical Center, Chicago, IL, ⁵Rheumatology, Hospital San Juan Batista, Catamarca, Argentina, Catamarca, Argentina, ⁶Instituto Reumatológico Strusberg, Córdoba, Argentina, ⁷Rheumatology, Universidad de Buenos Aires, Buenos Aires, Argentina, ⁸Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico, ⁹Rheumatology, Beaver Medical Group, Redlands, CA, ¹⁰Division of Rheumatology, Department of Internal Medicine, Loma Linda University, Loma Linda, CA, ¹¹Department of Psychology, University of Bologna, Bologna, Italy, ¹²National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ¹³Internal Medicine-Rheumatology, Gazi University Medical School, Ankara, Turkey, ¹⁴Rheumatology, University of Montreal, Montreal, QC, Canada, ¹⁵Rheumatology, University of Santo Tomas Hospital, Manila, Philippines, ¹⁶Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong, ¹⁷Division of Rheumatology, University of Calgary, Calgary, AB, Canada, ¹⁸Cedars-Sinai Medical Center Division of Rheumatology, Los Angeles, CA, ¹⁹Rheumatology, Cedars-Sinai Medical Center, Beverly Hills, CA
Background/Purpose: Although survival in SLE has improved, quality of life (QOL) remains poor. Physicians aim to reduce suffering and improve health outcomes, while maximizing efficiency…
Abstract Number: 2721 • 2016 ACR/ARHP Annual Meeting
Impact of Nail Psoriasis on Clinical Presentation of Psoriatic Arthritis—Descriptive Analysis from the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry
Philip J Mease¹, Jacqueline B. Palmer², Heather J. Litman³, Chitra Karki³ and Jeffrey D. Greenberg^3,4, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Novartis Pharmaceuticals Corporation, East Hanover, NJ, ³Corrona, LLC, Southborough, MA, ⁴New York University School of Medicine, New York, NY
Background/Purpose: Studies have shown that psoriasis of the skin, scalp and/or nails precedes the appearance of psoriatic arthritis (PsA) by up to 12 years1,2; however,…
Abstract Number: 2912 • 2016 ACR/ARHP Annual Meeting
Performance of the Patient-Reported Outcomes Measurement Information System (PROMIS) 29 in Systemic Sclerosis -Associated Interstitial Lung Disease (SSc-ILD)
Caitlyn Fisher^1,2, Rajaie Namas³, Amber Young², Holly Wilhalme⁴ and Dinesh Khanna⁵, ¹Cognitive Science / Creative Writing, Beloit College, Beloit, WI, ²Department of Internal Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, MI, ³Department of Medicine [Division of Rheumatology], University of Michigan, Ann Arbor, MI, ⁴University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁵University of Michigan, Ann Arbor, MI
Background/Purpose: PROMIS-29 is a generic health-related quality of life (HRQoL) instrument that was developed as part of the NIH Patient Reported Outcomes (PROs) Roadmap. Our…
Abstract Number: 303 • 2016 ACR/ARHP Annual Meeting
Knee Physical Exam Findings and Self-Reported Symptoms Are Associated with MRI-Detected Effusion-Synovitis Among Participants with or at Risk for Knee Osteoarthritis: Data from the Osteoarthritis Initiative (OAI)
Adam Berlinberg¹, Jordan Westra², Erin L. Ashbeck², Jaren Trost¹, Frank Roemer^3,4, Ali Guermazi⁵ and C. Kent Kwoh⁶, ¹Department of Medicine, University of Arizona, Tucson, AZ, ²The University of Arizona Arthritis Center, Tucson, AZ, ³Department of Radiology, Boston University School of Medicine, Boston, MA, ⁴Radiology, University of Erlangen, Erlangen, Germany, ⁵Boston University School of Medicine, Boston, MA, ⁶1501 N. Campbell Avenue, Room 8303, The University of Arizona Arthritis Center, Tucson, AZ
Background/Purpose: Inflammation has been implicated in the pathogenesis of KOA, but the relevance of physical exam findings and patient-reported symptoms of inflammation is unknown. Our…
Abstract Number: 445 • 2016 ACR/ARHP Annual Meeting
Performance of Promis Measures in a Multi-Ethnic Population-Based Systemic Lupus Erythematosus (SLE) Cohort
Patricia P. Katz¹, Jinoos Yazdany¹, Laura Trupin¹, Stephanie Rush², Cristina Lanata³, Charles G. Helmick⁴, Lindsey A. Criswell³ and Maria Dall'Era⁵, ¹Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ²UCSF, SF, CA, ³Division of Rheumatology, UCSF, San Francisco, CA, ⁴CDC, Atlanta, GA, ⁵Division of Rheumatology, University of California, San Francisco, San Francisco, CA
Background/Purpose: NIH’s PROMIS (Patient-Reported Outcomes Measurement Information System) measures have the potential to improve and expand outcomes measurement in SLE, but have not been tested…
Abstract Number: 531 • 2016 ACR/ARHP Annual Meeting
Disease Activity and Physical Fatigue As Related to Adherence and Health Literacy in Patients with Rheumatoid Arthritis
Jens Gert Kuipers¹, Michael Koller², Florian Zeman², Karolina Mueller³ and Ulrich Rueffer⁴, ¹Department of Rheumatology, Red Cross Hospital Bremen, Bremen, Germany, ²Center of Clinical Studies, University Hospital Regensburg, Regensburg, Germany, ³Center for Clinical Studies, University Hospital Regensburg, Regensburg, Germany, ⁴German Fatigue Society, Cologne, Germany
Disease activity and physical fatigue as related to adherence and health literacy in patients with rheumatoid arthritis J. G. Kuipers1, M. Koller2, F. Zeman2, K.…
Abstract Number: 1371 • 2016 ACR/ARHP Annual Meeting
Comparison of Patient and Physician Reported Global Disease Activity Measures in Juvenile Dermatomyositis
Heather Tory¹, David Zurakowski², Susan Kim³ and CARRA JDM Quality Measures Workgroup, ¹Rheumatology, Connecticut Children's Medical Center, Hartford, CT, ²Departments of Anesthesia and Surgery, Boston Children’s Hospital, Boston, MA, ³Division of Immunology, Boston Children's Hospital, Boston, MA
Background/Purpose: Patient reported outcomes (PROs) are becoming increasingly recognized as important in the care of patients with chronic diseases, such as Juvenile Dermatomyositis (JDM); however,…
Abstract Number: 1580 • 2016 ACR/ARHP Annual Meeting
Impact of Rituximab on Patient-Reported Outcomes in Patients with Rheumatoid Arthritis from the US Corrona Registry
Leslie R Harrold¹, Ani John², Jennie Best², Steve Zlotnick², Chitra Karki³, YouFu Li⁴, Jeffrey D. Greenberg⁵ and Joel Kremer⁶, ¹UMass Medical School, Worcester, MA, ²Genentech, Inc., South San Francisco, CA, ³Corrona, LLC, Southborough, MA, ⁴University of Massachusetts Medical School, Worcester, MA, ⁵New York University School of Medicine, New York, NY, ⁶The Center for Rheumatology, Albany Medical College, Albany, NY
Background/Purpose: Patients with rheumatoid arthritis (RA) experience diminished quality of life and increased disability. Patient-reported outcomes (PROs) are important measures of response to therapy in…
Abstract Number: 1683 • 2016 ACR/ARHP Annual Meeting
Influence of Axial Involvement on Clinical Characteristics of Psoriatic Arthritis—Descriptive Analysis from the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry
Philip J Mease¹, Chitra Karki², Mei Liu², Arthur Kavanaugh³, Renganayaki Pandurengan², Christopher T. Ritchlin⁴, Jacqueline B. Palmer⁵ and Jeffrey D. Greenberg^2,6, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Corrona, LLC, Southborough, MA, ³University of California San Diego, La Jolla, CA, ⁴Allergy, Immunology and Rheumatololgy Division, University of Rochester Medical Center, Rochester, NY, ⁵Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁶New York University School of Medicine, New York, NY
Background/Purpose: Although spinal involvement has been well studied in ankylosing spondylitis,1 very few studies in psoriatic arthritis (PsA) have characterized patients with axial involvement. The…
Abstract Number: 1759 • 2016 ACR/ARHP Annual Meeting
Sleep Disturbance Is Associated with Worsening Patient-Reported Outcomes over Two Years in Systemic Lupus Erythematosus (SLE)
Patricia P. Katz¹, Laura Trupin¹, Gabriela Schmajuk², Jinoos Yazdany¹, Edward H. Yelin¹ and Lindsey A. Criswell³, ¹Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ²San Francisco VA Medical Center, University of California, San Francisco, San Francisco, CA, ³Division of Rheumatology, UCSF, San Francisco, CA
Background/Purpose: Although studies to date have suggested sleep disturbance among individuals with SLE, prior studies have been small and have examined a limited number of…
Abstract Number: 2145 • 2015 ACR/ARHP Annual Meeting
Ixekizumab Improves Physical Function, Quality of Life, and Work Productivity in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients with Active Psoriatic Arthritis
Alice B. Gottlieb¹, Philip J. Mease², Raquel S. Cuchacovich^3,4, Catherine L. Shuler⁵, Chen-Yen Lin⁵, Russel T. Burge⁵, Suvajit Samanta⁵, Chin H. Lee⁵ and Dafna D. Gladman⁶, ¹Dermatology, Tufts Medical Center, Boston, MA, ²Department of Rheumatology, Swedish Medical Center and University of Washington, Seattle, WA, ³School of Medicine, Rheumatology Division, Indiana University, Indianapolis, IN, ⁴Bio Medicines Business Unit/Autoimmune Medical, Eli Lilly and Company, Indianapolis, IN, ⁵Eli Lilly and Company, Indianapolis, IN, ⁶Department of Medicine, Division of Rheumatology, University of Toronto, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis (PsA) is a chronic immune-mediated inflammatory disease associated with psoriasis, peripheral arthritis, enthesitis, dactylitis, and spondylitis. PsA has a significant negative impact…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].